|drug219||Analogs, Prostaglandin E1 Wiki||1.00|
|D055370||Lung Injury NIH||0.18|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial in the Fundación Santa Fe de Bogota
Description: Death during or at the end of the interventionMeasure: Mortality Time: 6 month
Description: Sat O2> 90% to the environmentMeasure: Hypoxemia Resolution Time: 6 month
Description: Number of days from admission to intensive care unit until administration of ANALOG PGE1Measure: Days from admission to intensive care unit and administration of ANALOG PGE1 Time: 6 month
Description: Specify number of days of ICU stayMeasure: ICU stay Time: 6 month
Description: Record days that the patient has received oxygen through a high flow systemMeasure: Days with high flow oxygen Time: 6 month
Description: Number of days during which the patient was under invasive or non-invasive mechanical ventilation prior to the administration of PGE1 ANALOGMeasure: Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG Time: 6 month
Description: Time from the onset of symptoms to the day of admissionMeasure: Evolution time of the disease Time: 6 month
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports